Purpose Urocortin (Ucn) exerts its actions through activation of two corticotropin-releasing factor receptors (CRFRs), CRFR1 and CRFR2. Involvement of Ucn/ CRFR2 system in pathophysiological conditions such as the regulation of angiogenesis and inhibition of proliferation has been already reported. Suppression of neovascularization through reduction of vascular endothelial growth factor and inhibition of tumor cell cycling is modulated mainly through activation of CRFR2. To Wnd out a possible involvement of Ucn/CRFR2 in kidney tumor, we examined the expression of Ucn and CRFR2 in normal and tumoral kidney specimens. Methods We applied reverse transcriptase PCR (n = 14), immunoXuorescence (IF) on tissue microarrays (n = 25) and confocal microscopy to examine the mRNA expression and peptide/protein localization of Ucn and CRFR2 in normal kidney versus clear cell renal cell carcinoma, respectively.
Introduction
The 40-amino acid neuropeptide urocortin (Ucn) belongs to the corticotropin-releasing factor (CRF) peptide family. Ucn was Wrst characterized in the rat hypothalamus and thereafter in several central and peripheral organs of rodents and mammals. It binds with high aYnity to both CRF receptor 1 (CRFR1) and 2 (CRFR2). CRF receptors (CRFRs) are G-protein coupled receptors and binding of Ucn stimulates cAMP production subsequently activating the protein kinase A (PKA) pathway [4, 19] . As does CRF, also Ucn binds with high aYnity to a soluble CRF binding protein (CRFBP). CRFBP is the only known example for a neuropeptide binding protein and although its exact physiological role still remains elusive, it is believed that CRFBP serves as a ligand reservoir to limit local actions of CRFrelated peptides [9] . While growth factors stimulating angiogenesis have been investigated in detail, endogenous inhibitors of angiogenesis are poorly understood. Activation of vascular CRFR2 by Ucn can eVectively suppress the vascularization through reduction of vascular endothelial growth factor (VEGF) [2] . As pathologic cell proliferation and neoangiogenesis are a pre-requisite for tumorigenesis and tumor progression, a link between the Ucn/CRFR system and human malignancies has been demonstrated [1, 5, 20] . In particular, it is believed that the inhibition of proliferation and the control of angiogenesis are mainly modulated through CRFR2 [7, 21] . Clear cell renal cell carcinoma (CC-RCC), an extremely angiogenic tumor accounting for about 3% of all adult neoplasms, is the most common malignancy and pathological subtype of the kidney and the urological cancer with the highest lethality [10, 16] .
To gain insight into the mechanisms underlying tumorigenesis of kidney tumor, we examined primarily the expression of Ucn and CRFR2, as responsible factors involved in cell proliferation and angiogenesis, in normal and corresponding tumoral specimens derived from CC-RCC.
Materials and methods

Tissue specimens and tissue microarray
Adult human kidney specimens (n = 25) were obtained primarily from peritumoral and tumoral tissues of adult patients undergoing nephrectomy with kidney tumors and arranged on tissue microarray (TMA) for IF or frozen immediately after excision for RNA isolation as described before [18] . Intact histomorphology as examined by pathologists was used to classify the specimens as normal. Histology of CC-RCC was approved by two pathologists. All specimens were obtained upon approval of the local ethical committee.
RNA isolation and reverse transcription PCR
Total RNA was extracted from frozen tissue samples (n = 14) and the quality of total RNA was controlled as described before [17] . Reverse transcriptase PCR was carried out using primers speciWc for Ucn, CRFR2, and beta-tubulin (TubA1b). Primer sequences are speciWed as following: Ucn with access no. of AF038633, sense: 5Ј-ACCGAGTCGAA TATGATGC-3Ј, antisense: 5Ј-CCTTCTCTGTCCATTGA CC-3Ј and predicted size of 113 bp, CRFR2 with access no. of Q13324, sense: 5Ј-GTACAGGAAGGCAGTGAAG-3Ј, antisense: 5Ј-AAGACAGACACGAAGAAACC-3Ј and predicted size of 163 bp. Tubulin A1b with access no. of AF081484, sense: 5Ј-CTC GGGCATAGTTATTGGC-3Ј, antisense: 5Ј-CCGGGC TGTGTTTGTAGAC-3Ј and predicted size of 128 bp. RT-PCR was carried out in duplicate after Superscript II RT and random hexamers (Invitrogen, Carlsbad, USA) and using 2 l of RT reaction product, 0.4 M of each primer, 1 unit Taq polymerase (Quiagen, Hilden, Germany), 0.2 mM dNTPs and 5.5 l of reaction buVer in a total volume of 25 l as described before [17] . Total RNA from human normal prostate (R1234201-P-BC) were obtained from Biochain Institute (Hayward, USA) as a positive control for Ucn [1] and CRFR2 [17] .
ImmunoXuorescence analysis and confocal microscopy
The paraYn-embedded tissue samples on TMA were stained for Ucn and CRFR2 protein expression using prediluted rabbit anti-human Ucn (ab27438, abcam, UK), and goat anti-human CRFR2 (sc-20550, Santa Cruz, CA, USA) and the standard avidin-biotin system according to the manufacturer's protocols (Vector Laboratories, Burlingame, CA, USA) with the exception that the peroxidase substrate diaminobenzidine was replaced by Atto 488 and Atto 655-labelled tyramides. Fluorochrome-labelled tyramides were produced by coupling of N-hydroxysuccinimide esters of Atto 488 and Atto 655 Xuorescence dyes (Atto-Tec, Siegen, Germany) with tyramine-hydrochloride (T2879, Sigma-Aldrich, Germany). ModiWcations of the protocols provided by the manufacturer and reported by Raap et al. [15] included that 30 l of a 40 mM dye solution in DMSO and 70 l of 15 mM tyramine-hydrochloride in 0.1 M borate buVer (pH 8.5) were incubated for 5 h at room temperature, as described before [17] . Atto 488 and Atto 655-labelled tyramides were applied for immunoXuorescence analysis without further puriWcation at a Wnal dilution of 1:200. Confocal laser scanning microscopy was carried out using a Leica DM IRE2 microscope. Triple Xuorescence was sequentially scanned after excitation at 405 nm (DAPI), 488 nm (Atto 488) and 633 nm (Atto 655). The imaris software was used to generate 3-dimensional images from the image stacks obtained by confocal laser microscopy.
Results
mRNA expression of Ucn and CRFR2 in normal kidney versus CC-RCC
Using reverse transcriptase PCR, speciWc signals for Ucn, and CRFR2 mRNAs were detected in both normal and tumoral samples (Fig. 1) . As an internal control, strong signal for TubA1b exhibited in all samples tested (Fig. 1) .
Moreover, negative controls did not produce any signals, whereas mRNA of Ucn and CRFR2 were readily detected in human prostate samples as positive control (Fig. 1) . Negative controls contained all reagents, except that 2-l H 2 O was substituted for reverse transcriptase in the RT reaction product (data not shown).
Peptide localization of Ucn in normal kidney and CC-RCC
We next examined the tissue distribution of Ucn in samples of normal and the tumoral counterpart on TMA slides using IF. In normal specimens, Ucn showed a cytoplasmic staining mainly in proximal tubules (Fig. 2a) . Interestingly, Ucn showed an inhomogeneous nuclear staining with diVering intensities in tumoral tissues (Fig. 3a-d) . To prove the speciWcity of this unexpected Wnding, the anti-Ucn antibodies were incubated overnight with synthetic human Ucn prior to application in IF. This pre-treatment completely eliminated the Ucn signal, conWrming the speciWcity of our Ucn detection method (Figs. 2b, 5b) . Moreover, epithelial cells of prostate exhibited an intense apical immunostaining for Ucn, further supporting that the signals for Ucn observed in kidney specimens are indeed speciWc (data not shown). Figure 3d shows a 3-D presentation of the nuclear occurrence of Ucn in tumoral specimens using stacks producing by confocal microscopy and imaris software to generate 3-D images.
Protein localization of CRFR2 in normal kidney and CC-RCC To characterize the expression pattern of CRFR2 in the vasculature of normal and tumoral specimens in more detail, we performed IF double staining for CRFR2 and CD31 (Figs. 2c-d, 4a-d ). CD31 was used as an endothelial cell marker to facilitate identiWcation of CRFR2 in microvessels. A cytoplasmic staining of CRFR2 could be observed in the epithelium of proximal tubules and in the vasculature of normal kidney (Fig. 2d) . In contrast, neither epithelial cells nor vasculature of tumor tissue were found to be positive for CRFR2 in nearly all probes examined (Fig. 4b, c) . The documented signals for CRFR2 could be omitted using a speciWc blocking experiment by blocking peptide of CRFR2 (sc-20550-P, Santa Cruz, CA, USA) (Fig. 5a ). This blocking experiment beside positive controls in heart and prostate specimens underlined the speciWcity of the CRFR2 immunoreactivity signals (data not shown). 
Discussion
There are very limited data on the expression of Ucn in human malignancies. Ucn expression is down-regulated in human endometrial carcinoma, whereas it was found to be unaltered in prostate adenocarcinoma in comparison to benign prostatic hyperplasia [1, 5] . Furthermore, both reports indicated a cytoplasmic staining of Ucn in tumor cells. In this study, we observed for the Wrst time that Ucn is present in diVerent subcellular compartments depending on whether the specimens are derived from normal or tumoral tissues. In normal specimens, cytoplasmic expression of Ucn was mainly observed in proximal tubules, whereas a diVuse nuclear immunostaining was detected in CC-RCC specimens. Transport across the nuclear envelope occurs through the nuclear pore complex (NPC). Small proteins are believed to cross the meshwork formed by nucleoporins by diVusion [6] . This may require the presence of nuclear localization signals (NLS). Thus, production of certain cofactors by diVerent cell types in diVerent stages of development or under special (patho)physiologic conditions can regulate which cargo is imported into the nucleus [14] . As a 40-amino acid peptide, it is likely that Ucn can passively pass the nuclear envelope and pores, and this may even apply to the Ucn precursor (26 kD). Open questions include whether there is an yet unidentiWed carrier protein involved in an active transport of Ucn into the nucleus. Although rather believed to be a secreted protein, even a potential involvement of CRFBP should not be excluded prematurely. There are several lines of evidence underscoring the importance of protein localization in cancer biology and target therapy [22] . Recently, Wang et al. demonstrated that the ErbB family proteins migrate into the nucleus of cancer cells where they can act as transcriptional factors and are closely related to cancer cell proliferation and metastasis [8] . Considering the inhomogeneous nuclear positivity of Ucn in tumoral tissues, a correlation study of Ucn nuclear positivity with clinicopathological parameters of CC-RCC specimens in a large number of patients collectively is of great interest. How the protein functions are regulated in diVerent cellular locations is not known. An intrinsic autonomous property of the protein along with diVerent binding factors in diVerent locations might be involved in this form of molecular traYcking.
Activation of vascular CRFR2 inhibits neovascularization in vivo and in vitro by reduction of VEGF [2, 7] . Tumor cells and vessels of CC-RCC demonstrated no signal for CRFR2 antibody (Fig. 4b, c) . Recently, we reported the same phenomenon in the vasculature of prostate carcinoma [17] . In contrast to CC-RCC, prostate cancer exhibited no signal for CRFR2 mRNA in PCR analysis. However, CC-RCC did not translate CRFR2 gene either. Thus, the CRFR2 mRNA and gene translation seem to be diVerentially regulated in diVerent cancer entities but in deed the CRFR2 is silenced at least in both CC-RCC and prostate cancer. Loss of CRFR2 expression in microvessels of CC-RCC, a known hypervascularized tumor, is in agreement with the Wnding that CRFR2-deWcient mice showed an extensive vascularization and increase in VEGF level in comparison to wild-type animals [2] . Moreover, treatment of CRFR2 wild-type animals with Ucn signiWcantly decreased the expression of VEGF [2] . Upregulation of VEGF and VEGF receptors in CC-RCC has been reported frequently. Inverse expression of CRFR2 and VEGF in renal cancer Wts to the mentioned CRFR2 knock out results and our present Wndings. It is therefore attractive to hypothesize that the systemic pharmacologic activation of CRFR2 represents a novel strategy for an anti-angiogenesis treatment of kidney tumors through inhibition of the vascularization of peritumoral tissues. This anti-progressive eVect may be further enhanced by an agonist-driven induction of CRFR2 expression within the microvasculature of kidney tumors. In support of this hypothesis, exposure of Lewis lung carcinoma cells to CRFR2-speciWc agonists in cell culture revealed an inducible expression of CRFR2 [7] .
Under normal conditions in the kidney, cell turnover is signiWcantly higher in distal tubules than in proximal tubules [11, 13] . Thus, co-localization of Ucn and CRFR2 in normal proximal tubules may reXect the antiproliferative action of the Ucn/CRFR2 system [3, 7] which seems to be disturbed in tumoral cells. Our Wndings further support the notion that the cell cycle regulatory function of a speciWc system strongly depends on the cell types involved and/or the subcellular localization. In particular, nuclear translocation can be cell cycle-dependent as shown for many Fig. 5 a, b show the blocking experiment and complete blockade of CRFR2 and Ucn signals in normal kidney and CC-RCC, respectively proteins regulating cell proliferation [12, 23, 24] . Therefore, it can be assumed that Ucn translocates into the nucleus to regulate the cell proliferation (independent of CRFR2) which it ultimately fails in cancer cells for yet unknown reasons.
Conclusions
In summary here, and for the Wrst time, we present the altered expression of Ucn/CRFR2 as an endogenous inhibitor of angiogenesis and proliferation, in human kidney cancer and this may improve the fundamental understanding of cancer target therapy and cancer biology.
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